𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cytological features of signet-ring cell carcinoma of the lung: Comparison with the goblet-cell-type adenocarcinoma of the lung

✍ Scribed by Koji Tsuta; Yasuo Shibuki; Naoki Maezawa; Naobumi Tochigi; Akiko Miyagi Maeshima; Yuko Sasajima; Hisao Asamura; Yoshihiro Matsuno


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
240 KB
Volume
37
Category
Article
ISSN
8755-1039

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Giant-cell carcinoma of the lung: A dedi
✍ Errol C. Friedberg πŸ“‚ Article πŸ“… 1965 πŸ› John Wiley and Sons 🌐 English βš– 616 KB

A D ed i fl e r e n t ia t e d A d en o c a z i n o m a ERROL c. FRIEDBERG," B S C . 5 I . B . B.CH. (RAND) INCE NASH AND STOUT'S^ DESCRIPTION OF 5 S cases of a form of lung cancer character-

Fine-needle aspiration cytologic feature
✍ Allan R. Smith; Stephen S. Raab; Rodney J. Landreneau; Jan F. Silverman πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 487 KB πŸ‘ 2 views

Pseudovascular adenoid squamous-cell carcinoma (PASCC) is an epithelial malignancy with spindle-cell features that can mimic vascular neoplasms, particularly angiosarcoma, in its morphologic characteristics. There have been only a few surgical pathology reports of PASCC arising in the lung, skin, an

Fine-needle aspiration cytology of large
✍ Jimenez-Heffernan, Jose A. ;Lopez-Ferrer, Pilar ;Vicandi, Blanca ;MariΓ±o, Adrian πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 322 KB πŸ‘ 2 views

BACKGROUND. The classification of pulmonary neuroendocrine neoplasms is particularly controversial. Large cell neuroendocrine carcinoma (LCNEC) has emerged as a separate entity among pulmonary endocrine neoplasms and the criteria for its histologic diagnosis are now well-described. However, cytologi

Treatment of small cell carcinoma of the
✍ Nixon, Daniel W. πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 282 KB

The COPP regimen (cyclophosphamide, Oncovin, procarbazine, prednisone) was one of the first chemotherapy programs to prolong survival in small cell lung cancer (SCLC) significantly. Results with this regimen in 50 patients with SCLC show an overall median survival of 10 months. Survival was decrease